Abstract
Objective
To evaluate change in quality of life in a community clinic ADHD population treated with atomoxetine or stimulants. No direct comparisons between atomoxetine and stimulants to improve quality of life in ADHD are available.
Methods
A prospective, nonrandomized comparison between ADHD patients treated with atomoxetine or stimulants in one clinic. Structured diagnostic assessment tools and a specific quality of life measure were used.
Results
84 patients (atomoxetine n = 39/stimulants n = 45), between the ages of 5 and 18, were treated for approximately 8 months. At end point, there were no significant differences in improvements of quality of life between the two groups. Age, participation in psychotherapy, and parental disability were not correlated with quality of life changes. Patients with lower baseline scores improved most.
Conclusions
Both atomoxetine and stimulants led to a modest increase in quality of life in this community clinic ADHD population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
`
Klassen AF, Miller A, Fine S: Health related quality of life in children and adolescents who have a diagnosis of ADHD. Pediatrics 114:e541–e547, 2004
Escobar R, Soutullo CA, Hervas A: Worse quality of life for children with newly diagnosed attention deficit hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 116:e364–e369, 2005
Perwien AR, Faries DE, Kratochvil CJ, et al.: Improvement in health-related quality-of-life in children with ADHD: an analysis of placebo-controlled studies of atomoxetine. Journal of Developmental and Behavioral Pediatrics 25:264–271, 2004
Lopez FA, Chandler MC, Biederman J, et al.: Long-term Adderall XR treatment improves quality of life in ADHD children. Abstract presented at the 156th annual meeting of the American Psychiatric Association, 2003
Bastiaens L, Dello Stritto C: Quality of life of children and adolescents during psychiatric treatment in a community mental health setting. Psychiatry 2:32–35, 2005
Bastiaens L: Effectiveness and tolerability of atomoxetine in a real-world ADHD population. Psychiatry 4(12):44–48, 2007
Sheehan DV, Lecrubier Y, Harnett Sheehan K, et al.: The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. European Psychiatry 12:232–241, 1997
Gadow KD, Sprafkin J: Adolescent Symptom Inventory-4. Stony Brook, NY, Checkmate Plus LTD, 1997
Bastiaens L, Dello Stritto C: Validity and reliability of the Health and Life Functioning Scale. Abstract presented at the 51st annual meeting of the American Academy of Child and Adolescent Psychiatry, 2004
Geller D, Donnelly C, Lopez F: Atomoxetine treatment for pediatric patients with attention deficit hyperactivity disorder and comorbid anxiety. Journal of the American Academy of Child and Adolescent Psychiatry 46(9):1119–1127, 2007
Prasad S, Harpin V, Poole L: A multicentre randomised open label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention deficit hyperactivity disorder. Current Medical Research and Opinion 23(2):379–394, 2007
Bastiaens L: Pediatric psychopharmacology in a capitated managed care system: how do patients fare? Journal of Child and Adolescent Psychopharmacology 8(2):115–124, 1998
Acknowledgements
No financial support was obtained for this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bastiaens, L. Both Atomoxetine and Stimulants Improve Quality of Life in an ADHD Population Treated in a Community Clinic. Psychiatr Q 79, 133–137 (2008). https://doi.org/10.1007/s11126-008-9070-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11126-008-9070-6